Mirxes Holding Company Limited (HKG:2629)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.41
-3.15 (-20.24%)
At close: Mar 31, 2026
Market Cap 3.66B
Revenue (ttm) 166.32M
Net Income (ttm) -598.38M
Shares Out 295.19M
EPS (ttm) -4.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,818,400
Average Volume 10,081,953
Open 15.80
Previous Close 15.56
Day's Range 12.38 - 17.08
52-Week Range 12.28 - 77.30
Beta n/a
RSI 31.69
Earnings Date Mar 31, 2026

About Mirxes Holding Company

Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 347
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2629
Full Company Profile

Financial Performance

In 2024, Mirxes Holding Company's revenue was $20.28 million, a decrease of -16.14% compared to the previous year's $24.19 million. Losses were -$92.33 million, 33.4% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.